Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | FASN | P49327 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 4/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.37 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16673480 | 0.84 | DGKA (0.51) | DGKAFAAHCETPMEN1KMT2A | |
| SCHEMBL3767547 | 0.84 | DGKA (0.51) | DGKAFAAHCETPMEN1KMT2A | |
| SCHEMBL18662306 | 0.84 | DGKA (0.51) | DGKAFAAHCETPMEN1KMT2A | |
| SCHEMBL5482400 | 0.84 | DGKA (0.51) | DGKAFAAHCETPMEN1KMT2A | |
| SCHEMBL31603951 | 0.79 | FASN (0.41) | FASNFAAHPPARGGPR132MEN1 | |
| SCHEMBL7199162 | 0.75 | FASN (0.47) | FASNFAAHALDH1A1TSHR | |
| SCHEMBL4831139 | 0.75 | FASN (0.47) | FASNFAAHALDH1A1TSHR | |
| SCHEMBL4831145 | 0.75 | FASN (0.47) | FASNFAAHALDH1A1TSHR | |
| SCHEMBL2012252 | 0.75 | FASN (0.53) | FASNFAAHPPARGGPR132MEN1 | |
| SCHEMBL20548597 | 0.75 | CNR1 (0.47) | DGKAFASNCETPPPARGGPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1160232-B1 | Process for production of monoalkyl ethers | KAO CORP (JP) | 2003-08-20 | — | — | EP | disclosed |
| US-6504063-B2 | Hydrogenation polyol in aqueous solution | KAO CORPORATION (JP) | 2003-01-07 | — | — | US | disclosed |
| US-20010056212-A1 | Process for production of monoalkyl ethers | KAO CORPORATION (JP) | 2001-12-27 | — | — | US | disclosed |
| EP-1160232-A2 | Process for production of monoalkyl ethers | Kao Corporation (JP) | 2001-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056212-A1 | Process for production of monoalkyl ethers | PHOSPHO1, HDHD5, PLTP | DGKA 48/4885FASN 231/4885FAAH 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.